These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27017789)

  • 1. [Interruption of biological drugs in patients affected with inflammatory diseases].
    Anttila VJ; Haapamäki J; Peltomaa R; Tiippana-Kinnunen T; Luosujärvi R
    Duodecim; 2016; 132(4):369-76. PubMed ID: 27017789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methotrexate therapy of inflammatory diseases. Reliable effects and recent developments in rheumatology, pneumology, gastroenterology and dermatology].
    Schnabel A; Dalhoff K; Stange EF; Mrowietz U; Gross WL
    Med Klin (Munich); 1995 Jun; 90(6):364-71. PubMed ID: 7637668
    [No Abstract]   [Full Text] [Related]  

  • 3. [Role of cytokines and their blocking in immune-mediated inflammatory diseases].
    Matikainen S; Jokiranta S; Eklund KK
    Duodecim; 2016; 132(4):349-54. PubMed ID: 27017787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review.
    Nieto JC; Arajol C; Carmona L; Marras C; Cea-Calvo L
    Immunotherapy; 2021 Apr; 13(5):433-458. PubMed ID: 33557600
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological therapies in autoimmune chronic inflammatory diseases (ACIDs).
    Ferraccioli GF; Gremese E
    Eur Rev Med Pharmacol Sci; 2006; 10(1):37-40. PubMed ID: 16494110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic human monoclonal antibodies in inflammatory diseases.
    Kotsovilis S; Andreakos E
    Methods Mol Biol; 2014; 1060():37-59. PubMed ID: 24037835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Special features of biological drug therapy in children].
    Aalto K; Leinonen S; Kolho KL; Lahdenne P
    Duodecim; 2016; 132(4):377-82. PubMed ID: 27017790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases.
    Pereira R; Raposo I; Nery F; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):285-287. PubMed ID: 29054331
    [No Abstract]   [Full Text] [Related]  

  • 10. [What have biological drugs changed in inflammatory rheumatic, skin and bowel diseases?].
    Hannonen P; Rantanen T; Jussila A
    Duodecim; 2016; 132(4):357-64. PubMed ID: 27017788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legionellosis and biologic therapies.
    Bodro M; Carratalà J; Paterson DL
    Respir Med; 2014 Aug; 108(8):1223-8. PubMed ID: 24975288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.
    Pincus T; Braun J; Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S1-3. PubMed ID: 24129127
    [No Abstract]   [Full Text] [Related]  

  • 13. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.
    Cantini F; Prignano F; Goletti D
    J Rheumatol Suppl; 2014 May; 91():78-82. PubMed ID: 24789004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
.
    Vergani HM; Calvini G; Mangini G; Mattioli F; Parodi A; Burlando M; Bodini G; Martelli A
    Int J Clin Pharmacol Ther; 2020 Apr; 58(4):208-213. PubMed ID: 32053103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
    Adelzadeh L; Jourabchi N; Wu JJ
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 17. [New therapy strategies].
    Müller-Ladner U; Tarner IH
    Z Rheumatol; 2013 Nov; 72(9):851-2. PubMed ID: 24193187
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel systemic drugs under investigation for the treatment of psoriasis.
    Gudjonsson JE; Johnston A; Ellis CN
    J Am Acad Dermatol; 2012 Jul; 67(1):139-47. PubMed ID: 22305044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art.
    Rahman M; Kumar V; Beg S; Sharma G; Katare OP; Anwar F
    Artif Cells Nanomed Biotechnol; 2016 Nov; 44(7):1597-608. PubMed ID: 26758815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not a cure, but a normal life].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(2):74. PubMed ID: 26961055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.